ALT

Altimmune's stock price has experienced significant fluctuations over the past six months, decreasing by 56.21% year-to-date and over the last six months. Key events impacting the stock include clinical trial data announcements, public offerings, earnings reports, FDA Breakthrough Therapy Designation for pemvidutide, and the Annual General Meeting. The stock has seen rallies leading up to data readouts, followed by drops if the market reception is unfavorable. Public offerings have introduced dilution risk, and earnings reports have sometimes been followed by modest declines. The company received FDA Breakthrough Therapy Designation for pemvidutide in March 2026 and held its Annual General Meeting on April 16, 2026.